|
注册号: Registration number: |
ChiCTR2500102143 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-09 10:03:26 |
|
注册时间: Date of Registration: |
2025-05-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
社区减盐干预的开发和验证 |
|
Public title: |
Development and validation of community salt reduction interventions |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
社区减盐干预的开发和验证——基于整群析因随机对照试验 |
|
Scientific title: |
Development and validation of community salt reduction interventions based on cluster factorial randomized controlled trials |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
祁娟 |
研究负责人: |
祁娟 |
|
Applicant: |
Qi Juan |
Study leader: |
Qi Juan |
|
申请注册联系人电话: Applicant telephone: |
+86 13560215443 |
研究负责人电话:
Study leader's |
+86 20 36062333 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
651545039@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
651545039@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市白云区启德路1号 |
研究负责人通讯地址: |
广州市白云区启德路1号 |
|
Applicant address: |
No. 1 Qide Road, Baiyun District, Guangzhou |
Study leader's address: |
No. 1, Qide Road, Baiyun District, Guangzhou,Guangdong,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州市疾病预防控制中心(广州市卫生监督所) |
||
|
Applicant's institution: |
Guangzhou Center for Disease Control and Prevention (Guangzhou Institute of Health Supervis |
||
|
研究负责人所在单位: |
广州市疾病预防控制中心 |
||
|
Affiliation of the Leader: |
Guangzhou Center for Disease Control and Prevention |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GZCDC-ECHR-2025P0014 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州市疾病预防控制中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guangzhou Center for Disease Control and Prevention |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-26 00:00:00 | ||
|
伦理委员会联系人: |
孙敏英 |
||
|
Contact Name of the ethic committee: |
Sun MinYing |
||
|
伦理委员会联系地址: |
广州市白云区启德路1号 |
||
|
Contact Address of the ethic committee: |
No. 1, Qide Road, Baiyun District, Guangzhou,Guangdong,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 36052333 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
sunmy1220@163.com |
|
研究实施负责(组长)单位: |
广州市疾病预防控制中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Guangzhou Center for Disease Control and Prevention |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市白云区启德路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1, Qide Road, Baiyun District, Guangzhou,Guangdong,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Project self-financing |
||||||||||||||||||||||
|
研究疾病: |
高血压 |
||||||||||||||||||||||
|
Target disease: |
hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
广州市社区高血压患者减盐项目,采用析因设计,旨在探索不同干预措施对居民减盐行为的影响。研究包含三个因子,每个因子有两个水平:减盐教具-减盐瓶(有VS无),减盐处方(有VS无),盐类(低钠盐VS无),共形成八组试验条件。通过这种设计,研究能够评估单一因子及其交互作用对减盐效果的影响,并找寻最佳的社区高血压患者控制血压非药物干预模式。 |
||||||||||||||||||||||
|
Objectives of Study: |
A factorial design was adopted to explore the effects of different interventions on residents' salt reduction behavior. The study included three factors, each of which had two levels: salt reduction teaching AIDS - salt reduction shaker (with VS without), salt reduction prescription (with VS without), and salt (low sodium salt VS without), forming a total of eight groups of test conditions. Through this design, the study was able to evaluate the influence of a single factor and its interaction on the effect of salt reduction, and identify the best non-drug intervention mode for blood pressure control in community hypertensive patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.干预期内由于有宜居外地或高流动倾向而不能接受慢病服务或可能中断监测者,定义为“因外出务工、升学、迁居等原因6个月或以上不在从化居住”; 2.合并慢性肾脏病3期及以上、心力衰竭II级及以上患者; 3.孕期或哺乳期妇女; 4.正在使用两种及以上引起高钾血症药物(如血管紧张素转化(ACEI)/血管紧张素II受体拮抗剂(ARBs)、盐皮质激素受体拮抗剂(螺内酯、非奈利酮)等); 5.干预过程中出现高钾血症终止研究者; 6.由于智力障碍、精神受损、活动能力不全或者无法交流等情况,难以就医或被调查者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. During the intervention period, those who could not receive chronic disease services or might interrupt monitoring due to their tendency to live in other places or high mobility were defined as "no longer living in Conghua for 6 months or more due to migrant work, study or relocation"; 2. Patients with chronic kidney disease stage 3 and above, heart failure grade II and above; 3. Pregnant or lactating women; 4. Are using two or more hyperkalemia inducing drugs (such as angiotensin converting (ACEI)/angiotensin II receptor antagonists (ARBs), salocorticoid receptor antagonists (spirenolactone, finelidone), etc.); 5. Hyperkalemia during the intervention terminated the investigator; 6. Access to medical care or the respondent is difficult due to conditions such as intellectual disability, mental impairment, immobility or inability to communicate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-05-20 00:00:00至 To 2026-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-20 00:00:00 至 To 2026-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究为整群随机,由独立于研究团队之外的统计学家使用电脑产生的随机数字,将从化和花都各8个地区分别随机分配至8个试验条件组中。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study was a cluster randomization, and eight districts in Conghua and Huadu were randomly assigned to eight experimental condition groups using computer-generated random numbers by statisticians independent of the research team. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签,对评估者设盲 |
|
Blinding: |
Open-label study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用REDcap系统进行数据收集:https://www.wcrcnet.cn/redcap/redcap_v15.2.1/Home/index.php |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection using the REDcap system: https://www.wcrcnet.cn/redcap/redcap_v15.2.1/Home/index.php |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |